2025-11-11T18:54:49-06:00 2024-12-31 346565596 ERNST & YOUNG US LLP 18101 VON KARMAN AVENUE SUITE 1700 IRVINE CA 92612 990 2024-01-01 954772979 CALIFORNIA HEART CENTER FOUNDATION CALI 3102488327 8670 WILSHIRE BOULEVARD SUITE 301 BEVERLY HILLS CA 90211 JON KOBASHIGAWA MD PRESIDENT 3102488327 2025-11-11 1 1 KARA ADAMS P00023315 9497942300 2024 2025-03-06 01:10:19Z JON KOBASHIGAWA MD 8670 WILSHIRE BOULEVARD SUITE 301 BEVERLY HILLS CA 90211 2858458 0 X WWW.CALHEART.ORG X 2000 CA PROMOTE & DEVELOP EDUCATIONAL & SCIENTIFIC RESEARCH TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE. 5 3 0 0 0 0 2875537 2115128 373961 743330 0 0 0 0 3249498 2858458 0 5000 0 0 2453159 2156580 0 0 0 684558 615798 3137717 2777378 111781 81080 984084 843523 284091 62450 699993 781073 X THE MISSION OF THE CALIFORNIA HEART CENTER FOUNDATION IS TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE THROUGH CLINICAL RESEARCH INITIATIVES AND EDUCATIONAL INITIATIVES. 0 0 2503870 5000 743330 THE MISSION OF THE CALIFORNIA HEART CENTER FOUNDATION IS TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE THROUGH CLINICAL RESEARCH INITIATIVES AND EDUCATIONAL INITIATIVES. EFFORTS INCLUDE THE PURSUIT OF COLLABORATIVE RESEARCH PROJECTS WHICH PROMOTE A DEEPER UNDERSTANDING OF DISEASE PROGRESSION AND TEST THE EFFICACY OF NEW STRATEGIES FOR DIAGNOSIS AND TREATMENT. AREAS OF RESEARCH CURRENTLY BEING PURSUED INCLUDE NON-INVASIVE METHODS TO DETECT ORGAN REJECTION, NOVEL IMMUNOSUPPRESSIVE AGENTS, IMMUNE MONITORING STRATEGIES, LONG-TERM COMPLICATIONS SUCH AS CARDIAC ALLOGRAFT VASCULOPATHY, (CONTINUED ON SCHEDULE O)(CONTINUATION FROM FORM 990, PAGE 2)NOVEL METHODS FOR ORGAN PROCUREMENT AND PRESERVATION, NEW MECHANICAL CIRCULATORY SUPPORT DEVICES AND PULMONARY HYPERTENSION. THE ORGANIZATION ALSO SUPPORTS IMPORTANT SCIENTIFIC SYMPOSIA, WHICH ALLOW FOR THE EXCHANGE OF IDEAS AMONG LEADERS IN THE FIELD AND PROVIDE A FORUM FOR EXPERTS TO SHARE THEIR EXPERIENCE AND KNOWLEDGE WITH OTHER PRACTITIONERS. THE ORGANIZATION RESOURCES ARE ALSO LEVERAGED TO SUPPORT A SUMMER RESEARCH INTERNSHIP PROGRAM FOR UNDERGRADUATE STUDENTS WITH AN INTEREST IN MEDICINE AND/OR ACADEMIC RESEARCH. FOLLOWING IS A SUMMARY OF PROJECTS AND PROGRAMS IMPLEMENTED IN 2024: SCIENTIFIC FORUMS AND EDUCATIONAL ACTIVITIES:* "SUCCESS WITH FAILURE: AN ADVANCED HEART DISEASE SYMPOSIUM" FEBRUARY 9TH, 2024 (CULVER CITY)THIS 1-DAY SYMPOSIUM ON ADVANCED HEART DISEASE TOOK PLACE ON FRIDAY, FEBRUARY 9TH, 2024 AT THE HILTON CULVER CITY. THE SYMPOSIUM PROVIDED AN IN-DEPTH REVIEW OF DIAGNOSTICS, THERAPEUTIC OPTIONS AND NOVEL TREATMENTS IN ADVANCED HEART FAILURE, MECHANICAL CIRCULATORY SUPPORT AND TRANSPLANTATION. THE PROGRAM DREW 176 ATTENDEES CONSISTING OF PHYSICIANS, ALLIED HEALTH PROFESSIONALS, INCLUDING NURSE PRACTITIONERS, TRANSPLANT COORDINATORS, PHYSICIAN ASSISTANTS, RNS AND CASE MANAGERS FROM ACROSS CALIFORNIA.* "AST FORUM: FELLOWSHIP TASK FORCE" FEBRUARY 24TH, 2024 (ARIZONA)SPONSORED AND HOSTED BY THE AMERICAN SOCIETY OF TRANSPLANTATION, THE AST FELLOWSHIP TASK FORCE FORUM WAS DESIGNED TO PROVIDE A PLATFORM FOR AN IN-DEPTH DISCUSSION ON THE CULTIVATION AND DEVELOPMENT OF TRAINEES. TO INCLUDE KEY STAKEHOLDERS IN ALL SOLID ORGAN TRANSPLANTATION (HEART, LUNG, LIVER, KIDNEY), THE MEETING FACILITATED A REVIEW OF FACTORS IMPACTING TRAINEES AND IDENTIFIED POTENTIAL INTERVENTIONS TO FURTHER PROMOTE THE FIELD. THE HOPE IS THAT THIS CONFERENCE WILL BE A FIRST STEP IN DEVELOPING A "TOOL KIT" TO ADDRESS BARRIERS AND CONCERNS THAT MAY INHIBIT THE PURSUIT OF SPECIALIZATION IN TRANSPLANTATION THAT CAN BE LEVERAGED BY INDIVIDUALS, INSTITUTIONS, AND ALLIED TRANSPLANT COMMUNITY GROUPS. (PUBLICATION OF MEETING REPORT PENDING.)* "CONSENSUS CONFERENCE: PRIMARY GRAFT DYSFUNCTION" APRIL 9TH, 2024 (PRAGUE)SPONSORED JOINTLY BY THE INTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION AND THE CALIFORNIA HEART CENTER/CEDARS-SINAI HEART INSTITUTE, THE 2024 CONSENSUS CONFERENCE ON PRIMARY GRAFT DYSFUNCTION WAS DESIGNED TO PROVIDE A FORUM FOR AN IN-DEPTH DISCUSSION AMONG THE LEADING EXPERTS IN THE FIELD, WITH A VIEW TO EVALUATING EVOLVING SCIENCE IN THIS AREA, AS PART OF AN UPDATE TO THE 2013 ISHLT CONSENSUS CONFERENCE ON PGD. THE HOPE IS THAT THIS CONFERENCE WILL PROVIDE A FORUM TO PROVIDE FURTHER GUIDANCE ON THE EFFICACY OF TREATMENT OPTIONS FOR PRIMARY GRAFT DYSFUNCTION, THE UTILITY OF RISK STRATIFICATION FOR PGD USING VARIOUS METHODOLOGIES, AND THE POTENTIAL OF REDUCING THE RISK OF PGD WITH THE ADVENT OF NEW TECHNOLOGIES FOR PROCUREMENT AND PRESERVATION OF DONOR HEARTS. (PUBLICATION OF CONSENSUS REPORT PENDING.)* "THOMAS D. GORDON VISITING PROFESSOR IN ADVANCED HEART DISEASE" OCTOBER 14TH-15TH, 2024. THIS ANNUAL VISITING PROFESSORSHIP HAS CONTINUED TO BE SPONSORED AND ORGANIZED BY DR. KOBASHIGAWA. THIS YEAR THE ORGANIZATION HAD THE HONOR OF HOSTING DR. ANDREAS ZUCKERMANN, INTERNATIONALLY RENOWNED CARDIOTHORACIC SURGEON AND DIRECTOR OF CARDIAC TRANSPLANTATION AT MEDICAL UNIVERSITY OF VIENNA. THIS VISIT, HELD OCTOBER 14TH-15TH, 2024 INCLUDED A GRAND ROUNDS LECTURE, ONE TO ONE FACULTY MEETINGS AND A FELLOWS' PROFESSIONAL DEVELOPMENT DISCUSSION. DR. ZUCKERMANN'S LECTURE ON "EX VIVO PERFUSION" WAS EXTREMELY WELL RECEIVED.* SUMMER RESEARCH INTERNSHIPS: UNDER THE SUPERVISION AND MENTORSHIP OF DR. JON KOBASHIGAWA, SUMMER HEART TRANSPLANT RESEARCH INTERNSHIPS HAVE BEEN OFFERED TO STUDENTS FOR THE SUMMER OF 2024. THESE INTERNSHIPS PROVIDE STUDENTS AT ALL LEVELS OF TRAINING AN OPPORTUNITY TO LEARN THE CLINICAL RESEARCH PROCESS, INCLUDING MEDICAL LITERATURE REVIEW, STUDY DESIGN, CHART REVIEW/DATA COLLECTION, DATA ANALYSIS, AND ABSTRACT DEVELOPMENT AND SUBMISSION. COMPLETED ABSTRACTS WERE SUBMITTED TO THE AMERICAN FEDERATION OF MEDICAL RESEARCH, A FORUM FOR JUNIOR INVESTIGATORS. THIS YEAR'S GROUP INCLUDES STUDENTS FROM:OHIO STATE UNIVERSITYPURDUE UNIVERSITYUNIVERSITY OF CALIFORNIA, BERKLEYUNIVERSITY OF CALIFORNIA, IRVINEUNIVERSITY OF CALIFORNIA, LOS ANGELESUNIVERSITY OF COLORADOUNIVERSITY OF SOUTHERN CALIFORNIA* HEART TRANSPLANT JOURNAL CLUBSJOURNAL CLUBS CONTINUE TO BE HELD IN A VIRTUAL FORMAT AND HAVE MAINTAINED STRONG PARTICIPATION, WITH AN AVERAGE ATTENDANCE OF 25 PEOPLE AT EACH SESSION. THE FOLLOWING SESSION(S) HAVE BEEN IMPLEMENTED OR SCHEDULED: MARCH 14TH, 2024 - 4:00PM - 5:00PM "DEVELOPMENT AND VALIDATION OF A RISK SCORE PREDICTING DEATH WITHOUT TRANSPLANT IN ADULT HEART TRANSPLANT CANDIDATES" PRESENTER: DR. ISABEL BALACHANDRAN CLINICAL RESEARCH:THIS SECTION IS FORMATTED BY CATEGORY; STUDY NAME; PRINCIPAL INVESTIGATOR (PI). 2503870 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 X 5 3 0 0 0 0 1 1 1 1 1 0 0 0 1 1 1 0 0 0 1 0 CA X DEBBIE BOTTEN 3104238473 6500 WILSHIRE BLVD 19TH FLOOR LOS ANGELES CA 90048 JON KOBASHIGAWA MD PRESIDENT 2.00 0.00 X X 0 0 0 MICHELE HAMILTON TREASURER 2.00 0.00 X X 0 0 0 THOMAS D GORDON DIRECTOR 1.00 2.00 X 0 84000 0 EDUARDO MARBAN MD DIRECTOR 1.00 50.00 X 0 4147273 397688 JAIME MORIGUCHI MD DIRECTOR 1.00 0.00 X 0 0 0 CHRISTINE SUMBI SECRETARY 40.00 0.00 X 0 264422 37095 SHRUTI SHANTHARAM DIRECTOR, RESEARCH OPERATIONS 40.00 0.00 X 0 192467 13967 ADAM DANIELS RESEARCH NURSE PRACTITIONER 40.00 0.00 X 0 172645 13892 VENISE STRAND PROGRAM MANAGER 40.00 0.00 X 0 136716 42955 PHYLLIS KATZ EXECUTIVE ASSISTANT 40.00 0.00 X 0 124857 21563 SAVANNAH MERSOLA RESEARCH SPECIALIST 40.00 0.00 X 0 119048 17119 IRINA COZIANU FORMER HIGHEST COMPENSATED 40.00 0.00 X 0 128493 35793 0 5369921 580072 0 1 1 0 0 2115128 2115128 EDUCATIONAL PROGRAMS 611430 743330 743330 743330 2858458 743330 0 0 5000 5000 270231 270231 1249575 1249575 636774 636774 1503 1052 451 6590 5931 659 514096 514096 43344 41177 2167 29438 29438 DUES & SUBSCRIPTIONS 10057 10057 BANK CHARGES 4509 4509 RENT/LEASE - EQUIPMENT 1886 1886 REPAIR & MAINTENANCE 1173 1173 3202 3202 2777378 2503870 273508 0 401818 418723 398 581134 173913 436659 407221 145209 17579 984084 843523 284091 62450 284091 62450 X 699993 781073 699993 781073 984084 843523 81080 0 X 0 0 0 X 2136097 2100269 2935423 2875537 2115128 12162454 2136097 2100269 2935423 2875537 2115128 12162454 12162454 12162454 1907038 1.00000 1.00000 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 473456 66235 407221 70594 70594 0 37084 37084 0 407221 0 1 0 0 0 0 0 0 0 EDUARDO MARBAN MD DIRECTOR 0 2594572 0 579284 0 973417 0 358833 0 38855 0 4544961 0 0 CHRISTINE SUMBI SECRETARY 0 221243 0 34846 0 8333 0 21364 0 15731 0 301517 0 0 SHRUTI SHANTHARAM DIRECTOR, RESEARCH OPERATIONS 0 164624 0 27828 0 15 0 5820 0 8147 0 206434 0 0 ADAM DANIELS RESEARCH NURSE PRACTITIONER 0 163047 0 9416 0 182 0 5509 0 8383 0 186537 0 0 VENISE STRAND PROGRAM MANAGER 0 120106 0 16461 0 149 0 12866 0 30089 0 179671 0 0 IRINA COZIANU FORMER HIGHEST COMPENSATED 0 123215 0 1235 0 4043 0 7495 0 28298 0 164286 0 0 PART I, LINE 3 PLEASE SEE SCHEDULE O NARRATIVE FOR PART VI, SECTION B LINE 15B. PART I, LINE 4B THE PLAN IS A SUPPLEMENTAL RETIREMENT ALLOWANCE THAT IS PAYABLE DIRECTLY TO THE PARTICIPANTS EACH QUARTER. THE BENEFIT FORMULA FOR THIS PLAN HAS ANNUAL CONTRIBUTIONS THAT ARE EITHER A PERCENTAGE OF SALARY, OR ARE DESIGNED TO FUND A PERCENTAGE OF THE ESTIMATED FINAL 5-YEAR AVERAGE SALARY. THE FOLLOWING DIRECTOR AND OFFICER RECEIVED PAYMENTS DURING THE YEAR ENDED DECEMBER 31, 2024: CHRISTINE SUMBI 7,845 EDUARDO MARBAN, MD 802,184 FORM 990, PART III, LINE 4A (CONTINUED) AMYLOIDOSIS; PHASE 3 GLOBAL, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ION-682884 IN PATIENTS WITH TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR CM); PATEL AMYLOIDOSIS; APOLLO-B: A STUDY TO EVALUATE PATISIRAN IN PATIENTS WITH TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY (ATTR AMYLOIDOSIS WITH CARDIOMYOPATHY); PATEL AMYLOIDOSIS; EIDOS -AG310-301 (A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF AG10 IN SUBJECTS WITH SYMPTOMATIC TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTRIBUTE-CM TRIAL)); PATEL AMYLOIDOSIS; CARDIAC AMYLOIDOSIS REGISTRY STUDY (MULTI-CENTER); PATEL AMYLOIDOSIS; AMYLOIDOSIS SURVEY; PATEL HEART FAILURE; A DOUBLE-BLIND, RANDOMIZED, SHAM-PROCEDURE-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY STUDY OF ALLOGENEIC MESENCHYMAL PRECURSOR CELLS (REXLEMESTROCEL-L) IN PATIENTS WITH CHRONIC HEART FAILURE DUE TO LEFT VENTRICULAR SYSTOLIC DYSFUNCTION OF EITHER ISCHEMIC OR NONISCHEMIC ETIOLOGY; CHANG HEART FAILURE; BARIATRIC SURGERY AND HEART FAILURE; HAMILTON HEART FAILURE; REDUCING LUNG CONGESTION SYMPTOMS USING THE V-WAVE SHUNT IN HEART FAILURE (RELIEVE HF); HAMILTON HEART FAILURE; RISK FACTORS AND OUTCOMES IN ADVANCED HEART DISEASE; KOBASHIGAWA HEART FAILURE; DCM PRECISION MEDICINE STUDY; KRANSDORF HEART FAILURE; DILATED CARDIOMYOPATHY PRECISION MEDICINE STUDY - CARDIAC MRI SUBSTUDY; KRANSDORF HEART TRANSPLANT; OCS HEART PERFUSION POST-APPROVAL REGISTRY OCS HEART PERFUSION POST- APPROVAL REGISTRY PROTOCOL; ESMAILIAN HEART TRANSPLANT; DCD-IIT EVALUATING THE SAFETY OF UTILIZING DONOR HEARTS FROM DONATION AFTER CIRCULATORY DEATH (DCD) DONORS COMPARED TO DONOR HEARTS FROM DONATION AFTER BRAIN DEATH (DBD) DONORS: A SINGLE CENTER PILOT STUDY; ESMAILIAN HEART TRANSPLANT; RANDOMIZED TRIAL TO COMPARE THE SHERPAPAK DEVICE VS COLD STORAGE OF DONOR HEARTS IN TRANSPLANTATION: A PILOT STUDY; ESMAILIAN HEART TRANSPLANT; THE FREQUENCY AND SIGNIFICANCE OF BLOOD TYPE A1 DONORS TO NON-A1 SUBGROUP RECIPIENTS IN HEART TRANSPLANTATION; KITTLESON HEART TRANSPLANT; ATG (A PILOT RANDOMIZED STUDY TO ASSESS THE EFFECT AND SAFETY PROFILE OF THYMOGLOBULIN IN PRIMARY CARDIAC TRANSPLANT RECIPIENTS: A 12-MONTH, SINGLE CENTER, RANDOMIZED, OPEN-LABEL STUDY OF EFFICACY COMPARING IMMEDIATE TREATMENT WITH AND WITHOUT THYMOGLOBULIN 1.5 MG/KG/D FOR 5 CONSECUTIVE DAYS IN HEART TRANSPLANT RECIPIENTS); KOBASHIGAWA HEART TRANSPLANT; SHORE (SURVEILLANCE HEARTCARE OUTCOMES REGISTRY); KOBASHIGAWA HEART TRANSPLANT; COMPUTER ASSISTED CARDIAC HISTOLOGIC EVALUATION; KOBASHIGAWA HEART TRANSPLANT; TARGETING INFLAMMATION AND ALLOIMMUNITY IN HEART TRANSPLANT RECIPIENTS WITH TOCILIZUMAB; KOBASHIGAWA AND PATEL HEART TRANSPLANT; INFILTRATING B CELLS IN CARDIAC ALLOGRAFT VASCULOPATHY; KRANSDORF HEART TRANSPLANT; IMMUNOLOGIC RISK STUDY; KRANSDORF HEART TRANSPLANT; DEVELOPMENT OF NON-INVASIVE CELL-FREE DNA TO SUPPLANT INVASIVE BIOPSY IN HEART TRANSPLANTATION-DEFINE-HT; KRANSDORF PULMONARY HYPERTENSION; RIOCIGUAT USERS REGISTRY - THE ROAR REGISTRY; HAGE PULMONARY HYPERTENSION; RIN-PH-304: PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INHALED TREPROSTINIL IN PATIENTS WITH PULMONARY HYPERTENSION DUE TO CHRONIC OBSTRUCTIVE PULMONARY DISEASE (PH-COPD); HAGE PULMONARY HYPERTENSION; AN OBSERVATIONAL STUDY TO CHARACTERIZE PATIENT GLOBAL IMPRESSION QUESTIONS FOR ACTIVITY-INDUCED SYMPTOMS IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION; HAGE HEART TRANSPLANT; ARTORIA STUDY: AN OBSERVATIONAL STUDY REGARDING THE OUTCOME OF ADULT PATIENTS WITH CONGENITAL HEART DISEASE (ACHD) OR INHERITED CARDIOMYOPATHIES UNDERGOING HEART OR HEART/LUNG TRANSPLANTATION; KOBASHIGAWA AMYLOIDOSIS; ALYNAM - ALN-TTR02-014 EXPANDED ACCESS PROTOCOL TO PROVIDE PATISIRAN TO PATIENTS WITH TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR AMYLOIDOSIS) WITH CARDIOMYOPATHY; PATEL HEART FAILURE; NOVONORDISK NN6019-4940: EFFICACY AND SAFETY OF NNC6019-0001 AT TWO DOSE LEVELS IN PARTICIPANTS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR CM); COLE PULMONARY HYPERTENSION; CADENCE - A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECTS OF SOTATERCEPT VERSUS PLACEBO FOR THE TREATMENT OF COMBINED POSTCAPILLARY AND PRECAPILLARY PULMONARY HYPERTENSION (CPC-PH) DUE TO HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF); HAGE HEART FAILURE; G-COR STUDY: GLOBAL CARDIO ONCOLOGY REGISTRY PROTOCOL; NIKOLOVA PULMONARY HYPERTENSION; INSMED_INS1009-202 A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF TREPROSTINIL PALMITIL INHALATION POWDER IN PARTICIPANTS WITH PULMONARY ARTERIAL HYPERTENSION; HAGE PULMONARY HYPERTENSION; INSMED_INS1009-203 AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND EFFECTIVENESS OF THE LONG-TERM USE OF TREPROSTINIL PALMITIL INHALATION POWDER IN PARTICIPANTS WITH PULMONARY ARTERIAL HYPERTENSION; HAGE PULMONARY HYPERTENSION; ASTRAZENECA_D8330C00003 A PHASE IIB RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTRE, DOSE-RANGING STUDY OF AZD3427 IN PARTICIPANTS WITH HEART FAILURE AND PULMONARY HYPERTENSION DUE TO LEFT HEART DISEASE (WHO GROUP 2); HAGE AMYLOID; ATTR IN LSS ANALYSIS OF LUMBAR SPINE STENOSIS SPECIMENS FOR IDENTIFICATION OF TRANSTHYRETIN CARDIAC AMYLOIDOSIS; KITTLESON HEART TRANSPLANT; PREGNANCY SURVEY PATIENT EDUCATION REGARDING PREGNANCY AFTER HEART TRANSPLANTATION; KITTLESON HEART TRANSPLANT; COVID VACCINATION STUDY ASSESSING THE CELLULAR AND HUMORAL RESPONSE TO SARS-COV-2 (COVID-19) VACCINATION IN HEART TRANSPLANT RECIPIENTS; KRANSDORF HEART FAILURE; CAV INFILTRATING B CELLS IN CARDIAC ALLOGRAFT VASCULOPATHY; KRANSDORF HEART FAILURE; IPSC STUDY INDUCED PLURIPOTENT STEM CELL CARDIOMYOCYTE; KRANSDORF PULMONARY HYPERTENSION; REM-PH-418_ARTISAN A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION); GEFT HEART TRANSPLANT; OPEN-LABEL TAFAMIDIS ATTR AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF TAFAMIDIS IN PATIENTS WITH TRANSTHYRETIN-MEDIATED AMYLOIDOSIS POST ORTHOTOPIC HEART TRANSPLANTATION; STERN HEART FAILURE; ECHONET SCREENING STUDY ARTIFICIAL INTELLIGENCE GUIDED ECHOCARDIOGRAPHIC SCREENING OF RARE DISEASES; STERN AMYLOID; AMYLOIDOSIS SURVEY IDENTIFYING AN ASSOCIATION BETWEEN ATHLETIC ACTIVITY AND CARDIAC AMYLOIDOSIS; STERN HEART TRANSPLANT; DSA PROJECT FUNCTIONAL CHARACTERIZATION OF POST HEART TRANSPLANT DE NOVO DONOR SPECIFIC ANTIBODIES (DNDSAS); NIKOLOVA HEART TRANSPLANT; ION-682884-CS12_OLE AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY OF EPLONTERSEN (ION-682884) IN PATIENTS WITH TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR-CM); NIKOLOVA HEART TRANSPLANT; G-COR GLOBAL CARDIO ONCOLOGY REGISTRY; NIKOLOVA HEART FAILURE; NOVONORDISK NN6019-7565 OPEN-LABEL EXTENSION STUDY OF LONG-TERM SAFETY AND EFFICACY OF NNC6019-0001 IN PARTICIPANTS WITH TRANSTHRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM); COLE FORM 990, PART IV, LINE 12 THE ORGANIZATION WAS INCLUDED IN A CONSOLIDATED, INDEPENDENT AUDITED FINANCIAL STATEMENTS FOR THE FISCAL YEARS ENDED 6/30/24 AND 6/30/25 DUE TO THE FACT THAT THE TAX YEAR OF ITS TAX-EXEMPT PARENT ORGANIZATION, CEDARS-SINAI MEDICAL CENTER, ENDS ON 6/30. THERE ARE NO AUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 12/31/24. FORM 990, PART VI, SECTION A, LINE 6 CEDARS-SINAI MEDICAL CENTER IS THE SOLE CORPORATE MEMBER OF CALIFORNIA HEART CENTER FOUNDATION. FORM 990, PART VI, SECTION A, LINE 7A CEDARS-SINAI MEDICAL CENTER, AS THE SOLE CORPORATE MEMBER, ELECTS BOARD OF DIRECTORS TO CALIFORNIA HEART CENTER FOUNDATION. FORM 990, PART VI, SECTION A, LINE 7B RESERVED RIGHTS OF CEDARS-SINAI MEDICAL CENTER, THE SOLE CORPORATE MEMBER OF THE ORGANIZATION. THE FOLLOWING ACTIONS MUST BE APPROVED OR ACTED UPON BY CEDARS-SINAI MEDICAL CENTER BEFORE BECOMING EFFECTIVE: (A) ANY SALE OR OTHER DISPOSITION OF ALL OR A SUBSTANTIAL PORTION OF THE ASSETS OF THE ORGANIZATION; (B) ANY MERGER OR AFFILIATION OF THE ORGANIZATION WITH ANY PERSON OR ENTITY OTHER THAN THE MEMBER; (C) ANY AMENDMENT TO THE ARTICLES OF INCORPORATION OR BYLAWS OF THE ORGANIZATION; (D) ANY ACT OR OMISSION WHICH CREATES ANY MATERIAL RISK TO THE MEMBER'S TAX-EXEMPT STATUS, OR CREATES ANY MATERIAL RISK OF A VIOLATION OF ANY STATE OR FEDERAL LAWS; (E) DISSOLUTION OF THE ORGANIZATION OR THE FILING OF ANY BANKRUPTCY PETITION; (F) CREATION OF ANY NEW CORPORATION, PARTNERSHIP OR ASSOCIATION; (G) ACQUISITION OF OR THE INVESTMENT IN A NEW OPERATING BUSINESS; (H) ENTERING INTO ANY PARTNERSHIPS OR JOINT VENTURES; (I) ADOPTION OF OR CHANGES TO OPERATING OR CAPITAL BUDGETS; (J) ADOPTION OF THIS CORPORATION'S POLICIES AND PROCEDURES; (K) EXECUTION AND DELIVERY OF ANY NEW AFFILIATION AGREEMENTS AND OTHER RELATIONSHIPS WITH THE UCLA SCHOOL OF MEDICINE AND OTHER INSTITUTIONS OF MEDICAL LEARNING; (L) UNBUDGETED CAPITAL EXPENDITURES OVER $100,000; (M) LOANS, BORROWINGS OR GUARANTEES IN EXCESS OF $100,000, UNLESS APPROVED IN THE BUDGET; (N) ANY SECURITY INTERESTS OR MORTGAGES ON THE PROPERTY OF ORGANIZATION; (O) OPERATING OR CAPITAL LEASES WHERE THE TERM IS OVER FIVE YEARS OR THE TOTAL OBLIGATION UNDER THE LEASE EXCEEDS $100,000, UNLESS APPROVED IN THE BUDGET; (P) TERMINATION OR SELECTION OF THE AUDITORS OF THE ORGANIZATION; (Q) APPOINTMENT OR REMOVAL OF ANY MEMBER OF THE BOARD (OTHER THAN EX-OFFICIO DIRECTORS); (R) APPOINTMENT OF REMOVAL OF ANY OFFICERS; (S) EXECUTION AND DELIVERY OF ANY PROFESSIONAL SERVICE AGREEMENTS; (T) RELOCATION OF PRINCIPAL OFFICE; AND (U) FIXING THE NUMBER OF DIRECTORS OF THE ORGANIZATION. FORM 990, PART VI, SECTION B, LINE 11B THE ORGANIZATION'S FORM 990 UNDERGOES AN INTENSE AND HIGHLY COMPREHENSIVE REVIEW PROCESS. THE REVIEW INVOLVES VARIOUS MANAGEMENT PERSONNEL AND A BIG FOUR ACCOUNTING FIRM. FORM 990, PART VI, SECTION B, LINE 12C CONFLICT OF INTEREST POLICY ANNUAL STATEMENTS: EACH DIRECTOR, OFFICER, MEMBER OF A COMMITTEE WITH BOARD-DELEGATED POWERS AND ANY OTHER INTERESTED PERSON AS DETERMINED BY THE BOARD OR COMMITTEE SHALL AT LEAST ANNUALLY SIGN A COPY OF THE "STATEMENT PERTAINING TO CONFLICT OF INTEREST." IF A DIRECTOR, OFFICER, OR COMMITTEE MEMBER, OR DESIGNATED INTERESTED PERSON BECOMES AWARE THAT A POTENTIAL OR APPARENT CONFLICT MAY EXIST WHICH IS NOT DISCLOSED ON SUCH A STATEMENT, IT SHALL BE THE RESPONSIBILITY OF THE INTERESTED PERSON TO DISCLOSE THE POTENTIAL CONFLICT TO THE PRESIDENT AND TO THE BOARD OR APPROPRIATE COMMITTEE AND AS SET FORTH ABOVE, PRIOR TO ANY BOARD OR COMMITTEE DISCUSSIONS OR ACTION WITH RESPECT TO THE RELEVANT TRANSACTION OR ARRANGEMENT, AND, IF RELEVANT, TO LEAVE THE MEETING DURING THE DISCUSSION AND VOTE ON THE TRANSACTION OR ARRANGEMENT. DETERMINING WHETHER A CONFLICT OF INTEREST EXISTS: IF CONSIDERATION OF THE TRANSACTION OR ARRANGEMENT AT ISSUE IS A MATTER WITHIN THE SCOPE OF AUTHORITY OF THE BOARD OF DIRECTORS OR A COMMITTEE, AFTER DISCLOSURE OF THE FINANCIAL INTEREST AND AFTER ANY DISCUSSION WITH THE INTERESTED PERSON, THE RELEVANT CALIFORNIA HEART CENTER FOUNDATION ("CHCF") OFFICER OR ADMINISTRATOR SHALL DETERMINE WHETHER A CONFLICT OF INTEREST EXISTS. IF IT IS DETERMINED THAT A CONFLICT OF INTEREST EXISTS AND, NOTWITHSTANDING THE CONFLICT, THE CHCF OFFICER OR ADMINISTRATOR DETERMINES THAT IT CONTINUES TO BE IN THE BEST INTERESTS OF CHCF TO PROCEED WITH THE TRANSACTION OR ARRANGEMENT AT ISSUE, THE CHCF OFFICER OR ADMINISTRATOR SHALL REFER THE TRANSACTION OR ARRANGEMENT TO THE BOARD OR THE APPROPRIATE BOARD-DESIGNATED COMMITTEE FOR EVALUATION. ALTERNATIVELY IF CONSIDERATION OF THE TRANSACTION OR ARRANGEMENT AT ISSUE IS A MATTER WITHIN THE SCOPE OF THE AUTHORITY OF THE BOARD OF DIRECTORS OR A COMMITTEE, THE INTERESTED PERSON SHALL LEAVE THE BOARD OR COMMITTEE MEETING WHILE THE DETERMINATION OF THE EXISTENCE OF A CONFLICT OF INTEREST IS DISCUSSED AND VOTED UPON. THE REMAINING BOARD OR COMMITTEE MEMBERS SHALL DECIDE, BY MAJORITY VOTE, IF A CONFLICT OF INTEREST EXISTS. PROCEDURES FOR ADDRESSING THE CONFLICT OF INTEREST: A. AN INTERESTED PERSON MAY MAKE A PRESENTATION TO THE BOARD OR COMMITTEE REGARDING THE TRANSACTION OR ARRANGEMENT. AFTER SUCH PRESENTATION THE INTERESTED PERSON MUST LEAVE THE MEETING DURING THE DISCUSSION OF, AND THE VOTE ON THE TRANSACTION OR ARRANGEMENT. B. THE CHAIR OF THE BOARD OR COMMITTEE SHALL, IF DEEMED APPROPRIATE BY THE BOARD OR COMMITTEE, APPOINT A DISINTERESTED PERSON OR COMMITTEE TO INVESTIGATE ALTERNATIVES TO THE PROPOSED TRANSACTION OR ARRANGEMENT. C. AFTER EXERCISING DUE DILIGENCE, THE BOARD OR COMMITTEE SHALL DETERMINE WHETHER CHCF CAN OBTAIN A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT WITH REASONABLE EFFORTS FROM A PERSON OR ENTITY THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. D. IF A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT IS NOT REASONABLY ATTAINABLE UNDER CIRCUMSTANCES THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST, THE BOARD OR COMMITTEE SHALL DETERMINE BY A MAJORITY VOTE OF THE DISINTERESTED DIRECTORS WHETHER THE TRANSACTION OR ARRANGEMENT IS IN CHCF' BEST INTEREST AND FOR ITS OWN BENEFIT AND WHETHER THE TRANSACTION IS FAIR AND REASONABLE TO CHCF AND SHALL MAKE ITS DECISION AS TO WHETHER TO ENTER INTO THE TRANSACTION OR ARRANGEMENT IN CONFORMITY WITH SUCH DETERMINATION. VIOLATIONS OF THE CONFLICTS POLICY: A. IF THE BOARD OR COMMITTEE HAS REASONABLE CAUSE TO BELIEVE THAT A MEMBER OF THE BOARD OR COMMITTEE OR AN OFFICER OR OTHER INTERESTED PERSON HAS FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, IT SHALL INFORM THE MEMBER OR OFFICER OR INTERESTED PERSON OF THE BASIS FOR SUCH BELIEF AND AFFORD SUCH PERSON AN OPPORTUNITY TO EXPLAIN THE ALLEGED FAILURE TO DISCLOSE. B. IF, AFTER HEARING THE RESPONSE OF SUCH PERSON AND MAKING SUCH FURTHER INVESTIGATION AS MAY BE WARRANTED IN THE CIRCUMSTANCES, THE BOARD OR COMMITTEE DETERMINES THAT SUCH PERSON HAS IN FACT FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, IT SHALL TAKE APPROPRIATE DISCIPLINARY AND CORRECTIVE ACTION. FORM 990, PART VI, SECTION B, LINE 15B THE EXECUTIVE PERSONNEL COMMITTEE (THE COMMITTEE) OF THE TAX-EXEMPT PARENT OF THE ORGANIZATION, CEDARS-SINAI MEDICAL CENTER, IS A STANDING COMMITTEE OF THE BOARD OF DIRECTORS. THE COMMITTEE ADDRESSES COMPENSATION AND BENEFITS REGARDING THE ORGANIZATION'S OFFICERS AND BOARD MEMBERS WHO ARE ALSO EXECUTIVE EMPLOYEES AND CONTRACTUALLY ENGAGED FACULTY OF THE MEDICAL CENTER, AND IS AUTHORIZED BY THE BOARD OF DIRECTORS TO ACT WITH RESPECT TO SUCH ISSUES. THE COMMITTEE EVALUATES THE PERFORMANCE AND APPROVES THE COMPENSATION AND BENEFITS FOR THE ORGANIZATION'S OFFICERS AND BOARD MEMBERS WHO ARE ALSO EXECUTIVE EMPLOYEES AND CONTRACTUALLY ENGAGED FACULTY OF THE MEDICAL CENTER. EACH YEAR, THE COMMITTEE FOLLOWS A PROCESS THAT ENSURES THAT THE COMPENSATION AND BENEFITS IS REASONABLE AND IN COMPLIANCE WITH APPLICABLE LAWS AND REGULATIONS. THE MEDICAL CENTER'S SVP OF HR PROVIDES STAFF SUPPORT TO THE COMMITTEE. THE COMMITTEE MAY ENGAGE AN INDEPENDENT COMPENSATION AND BENEFITS CONSULTANT, AND ANY OTHER ADVISORS IT DEEMS NECESSARY. THE COMMITTEE MAY ALSO ENGAGE INDEPENDENT COUNSEL. THE MEDICAL CENTER WILL PROVIDE FOR APPROPRIATE FUNDING FOR PAYMENT OF COSTS TO ANY SUCH PERSONS RETAINED BY THE COMMITTEE. ANNUALLY, AT THE COMMITTEE'S DIRECTION, THE INDEPENDENT COMPENSATION CONSULTANT SHALL PREPARE SUCH REPORTS AS THE COMMITTEE REASONABLY DEEMS NECESSARY. AT A MINIMUM, SUCH REPORTS WILL INCLUDE MARKET SURVEY DATA FROM A PEER GROUP DESIGNATED BY THE COMMITTEE, WHICH SHALL BE CONSIDERED BY THE COMMITTEE PRIOR TO MAKING DECISIONS. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S CONFLICT OF INTEREST POLICY AND GOVERNING DOCUMENTS ARE NOT AVAILABLE TO THE PUBLIC AND ITS TAX-EXEMPT PARENT'S AUDITED CONSOLIDATED FINANCIAL STATEMENTS ARE ATTACHED TO THE PARENT'S FORM 990. CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BOULEVARD LOS ANGELES CA 90048 951644600 ACUTE-CARE, TEACHING AND RESEARCH HOSPITAL CA 501(C)(3) LINE 3 CEDARS-SINAI HEALTH SYSTEM 0 CEDARS-SINAI MEDICAL CARE FOUNDATION 6500 WILSHIRE BLVD 19TH FLOOR LOS ANGELES CA 90048 954457756 PROVISION OF MEDICAL CARE, TEACHING AND RESEARCH CA 501(C)(3) LINE 12A, I CEDARS-SINAI MEDICAL CENTER 1 KERLAN-JOBE ORTHOPAEDIC FOUNDATION 6801 PARK TERRACE 500 LOS ANGELES CA 90045 954707606 EDUCATION AND RESEARCH RELATED TO ORTHOPAEDIC MEDICINE CA 501(C)(3) LINE 7 CEDARS-SINAI MEDICAL CARE FOUNDATION 1 SANTA MONICA ORTHOPAEDIC & SPORTS MED RESEARCH FDN 2020 SANTA MONICA BLVD 4TH FLR SANTA MONICA CA 90404 954789926 EDUCATION AND RESEARCH RELATED TO ORTHOPAEDIC AND NEUROLOGIC CONDITIONS CA 501(C)(3) PF CEDARS-SINAI MEDICAL CARE FOUNDATION 1 CEDARS-SINAI MARINA HOSPITAL 4650 LINCOLN BLVD MARINA DEL REY CA 90292 201645949 HEALTH SERVICES CA 501(C)(3) LINE 3 CEDARS-SINAI MEDICAL CENTER 1 CEDARS-SINAI HEALTH SYSTEM 6500 WILSHIRE BLVD SUITE 2400 LOS ANGELES CA 90048 300990905 SUPPORT SPECIFIED NONPROFIT HEALTHCARE ORGANIZATIONS CA 501(C)(3) LINE 12C, III-FI N/A 0 TORRANCE HEALTH ASSOCIATION 3330 LOMITA BLVD TORRANCE CA 90505 330073515 HEALTH SERVICES CA 501(C)(3) LINE 12B, II CEDARS-SINAI HEALTH SYSTEM 1 TORRANCE MEMORIAL MEDICAL CENTER HEALTH CARE FOUNDATION 3330 LOMITA BLVD TORRANCE CA 90505 953528452 FUNDRAISING CA 501(C)(3) LINE 7 TORRANCE HEALTH ASSOCIATION 1 TORRANCE MEMORIAL MEDICAL CENTER 3330 LOMITA BLVD TORRANCE CA 90505 951644042 HEALTH SERVICES CA 501(C)(3) LINE 3 TORRANCE HEALTH ASSOCIATION 1 CEDARS SINAI INTELLECTUAL PROPERTY COMPANY 8700 BEVERLY BOULEVARD LOS ANGELES CA 90048 871097792 MANAGEMENT AND LICENSING OF INTELLECTUAL PROPERTY ASSETS CA 501(C)(3) 12A, I CEDARS-SINAI MEDICAL CENTER 1 PASADENA HOSPITAL ASSOCIATION LTD 100 WEST CALIFORNIA BLVD PASADENA CA 91105 951644036 HEALTH SERVICES CA 501(C)(3) LINE 3 CEDARS-SINAI HEALTH SYSTEM 1 HUNTINGTON MEDICAL FOUNDATION 100 WEST CALIFORNIA BLVD PASADENA CA 91105 954434428 HEALTH SERVICES CA 501(C)(3) LINE 3 PASADENA HOSPITAL ASSOCIATION LTD 1 CEDARS SINAI HEALTH VENTURES 8700 BEVERLY BLVD LOS ANGELES CA 90048 883506667 MANAGEMENT OF HEALTH INNOVATIONS CA 501(C)(3) 12A, I CEDARS-SINAI MEDICAL CENTER 1 ENDOSCOPY CENTER OF SANTA MONICA LLC 12400 WILSHIRE BLVD SUITE 100 LOS ANGELES CA 90025 113652210 ENDOSCOPIES AND RELATED PROCEDURES CA N/A 0 0 ISS ASC HOLDINGS LLC 6500 WILSHIRE BLVD 19TH FLOOR LOS ANGELES CA 90048 471890805 INVESTMENT IN HEALTHCARE SERVICES CA N/A 0 0 CS-BH ASC HOLDINGS LLC 450 N ROXBURY DR SUITE 602 BEVERLY HILLS CA 90210 812246488 HOLDING COMPANY CA N/A 0 0 INTERNATIONAL SPINE & ORTHOPEDIC INSTITUTE LLC 8500 W 110TH ST OVERLAND PARK KS 66210 263738893 SPINE AND ORTHOPEDIC INSTITUTE DE N/A 0 0 SANTA MONICA IMAGING GROUP LLC 6500 WILSHIRE BLVD 19TH FLOOR LOS ANGELES CA 90048 820760657 IMAGING CENTER CA N/A 0 0 TORRANCE MEMORIAL SURGICAL CENTER LLC I 23560 CRENSHAW BLVD SUITE 104 TORRANCE CA 90505 465259260 OUTPATIENT SURGICAL SERVICES CA N/A 0 0 3565 DEL AMO ASSOCIATES A CALIFORNIA LIMITED PARTNERSHIP 5017 CARMEN STREET TORRANCE CA 90503 330554737 RENTAL REAL ESTATE CA N/A 0 0 90210 ASC VENTURE LLC 450 N ROXBURY DR SUITE 602 BEVERLY HILLS CA 90210 134341801 AMBULATORY SURGERY CENTER CA N/A 0 0 ABCENTRA LLC 2390 CRENSHAW BLVD 202 TORRANCE CA 90501 202327127 RESEARCH AND DEVELOPMENT DE N/A 0 0 TIA-CEDARS MANAGEMENT SERVICES ORGANIZATION LLC 548 MARKET ST SUITE 45295 SF CA 94104 884206382 INVESTMENT IN HEALTHCARE SERVICES CA N/A 0 0 K HEALTH-CEDARS MANAGEMENT SERVICES ORGANIZATION LLC 6500 WILSHIRE BLVD STE 2250 LA CA 90048 932305005 HEALTHCARE MANAGEMENT SERVICES CA N/A 0 0 PASADENA ASC VENTURE LLC 6500 WILSHIRE BLVD 19TH FLOOR LOS ANGELES CA 90048 991582374 AMBULATORY SURGERY CENTER CA N/A 0 0 OPTIMATRIX HEALTH SOLUTIONS INC 8700 BEVERLY BLVD LOS ANGELES CA 90048 954522779 INACTIVE CA N/A C 1 CONGRESS SERVICES CORPORATION 100 WEST CALIFORNIA BLVD PASADENA CA 91105 953978299 MANAGEMENT SERVICES CA N/A C 1 GRAVIDAS DIAGNOSTICS INC 700 N SAN VICENTE BLVD SUITE G-700 WEST HOLLYWOOD CA 90069 872085657 MEDICAL EQUIPMENT AND SUPPLIES MANUFACTURING DE N/A C 1 THIRD STREET INSURANCE COMPANY (SAC) LTD PO BOX HM 1024 HAMILTON HM DX BD 981678749 CAPTIVE INSURANCE BD N/A C 1 LIQUID LOAN OPPORTUNITIES FUND LP PO BOX 309 UGLAND HOUSE GRAND CAYMAN CJ KY1-1104 980693063 INVESTMENTS CJ N/A C 1 CORONET VENTURES (SINGAPORE) PTE LTD 112 ROBINSON ROAD 04-02 ROBINSON SINGAPORE SN 068902 HEALTHCARE AND BIOMEDICAL INNOVATION INVESTMENTS SN N/A C 1 CEDARS-SINAI UK LTD 66 LINCOLNS INN FIELDS LONDON UK WC2A 3LH CLINIC OPERATOR UK N/A C 1 0 0 1 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 CEDARS-SINAI MEDICAL CARE FOUNDATION N 1948597 FAIR MARKET VALUE